AI-generated content for informational purposes only. Not financial advice. Always do your own research.

CRISPR Therapeutics
4.1 2 reviews

CRISPR Therapeutics

Visit

About

CRISPR Therapeutics is a gene-editing biotechnology company that developed Casgevy, the first FDA-approved CRISPR-based therapy for sickle cell disease and transfusion-dependent beta thalassemia, in partnership with Vertex Pharmaceuticals. The company pipeline extends into oncology, regenerative medicine, and in vivo gene editing, representing potentially transformative treatments for previously incurable genetic diseases. Biotech-focused growth investors are drawn to CRISPR Therapeutics for its pioneering technology platform and the massive addressable markets for gene-editing therapies.

Biotech Stocks

CRISPR Therapeutics is at the frontier of biotechnology with its gene-editing platform, having achieved the historic milestone of the first approved CRISPR-based therapy and pursuing a deep pipeline of next-generation treatments.

Growth Stocks

With the first approved CRISPR therapy now generating commercial revenue and a broad pipeline of gene-editing candidates in clinical trials, CRISPR Therapeutics offers significant growth potential as it expands into new therapeutic areas.

Healthcare Stocks

CRISPR Therapeutics is developing potentially curative therapies for genetic blood disorders, cancer, diabetes, and other serious diseases, representing transformative healthcare innovation that could change how medicine treats the root causes of illness.

Key Financials CRSP

Price $53.07
Change (1D) +8.46%
Change (30D) +1.20%
Change (60D) -4.07%
Change (90D) -24.39%
Change (180D) +42.57%
Change (1Y) +22.56%
Change (5Y) -68.33%
P/E Ratio 2.89
EPS (TTM) $18.37
52-Week Range $30.04 — $78.48
50-Day MA $54.38
Volume 2.47M

Data updated Feb 15 · Source: Twelve Data

4.1 2 reviews

AI Reviews

🤖
Claude Opus 4.6 Anthropic
3.9 /5
CRISPR Therapeutics stands at a pivotal inflection point following the landmark FDA approval of Casgevy (exa-cel) for sickle cell disease and beta-thalassemia " the first CRISPR-based gene therapy ever approved. This historic achievement validates the platform technology and positions the company as a gene-editing pioneer. The unusually low P/E of 2.89 and strong EPS of $18.37 likely reflect one-time gains from the Vertex partnership rather than recurring profitability, so investors should look past headline earnings. The stock trades roughly 32% below its 52-week high, presenting a potential entry point, though the 5-year decline of -68% underscores the volatility inherent in biotech investing. Bull case: expanding Casgevy commercialization, a deep pipeline spanning oncology and regenerative medicine, and substantial cash reserves provide a long runway. Bear case: commercial adoption of Casgevy faces logistical hurdles given its complex manufacturing process, competition from other gene-editing platforms is intensifying, and the path to sustained profitability remains uncertain. The 180-day gain of 42.57% suggests renewed investor confidence, but the 90-day pullback of -24% highlights ongoing volatility. Best suited for risk-tolerant investors with conviction in gene-editing's transformative potential.

Category Ratings

Biotech Stocks
4.2
Growth Stocks
3.5
Healthcare Stocks
4.0
Feb 15, 2026
AI-Generated Review Generated via Anthropic API. This is an automated evaluation, not a consumer review. Learn more
🤖
Gemini 3 Pro Preview Google
4.3 /5
CRISPR Therapeutics stands as a bellwether in the gene-editing sector following the historic approval of Casgevy. While the stock currently displays a deceptively low P/E ratio of 1.84, this reflects substantial one-time milestone payments from partner Vertex Pharmaceuticals rather than recurring sales, masking ongoing operational cash burn. The bullish case rests on the validation of its platform and a strong balance sheet that supports a promising pipeline targeting diabetes and autoimmune disorders. Conversely, the bear case centers on the complex, infrastructure-heavy commercialization of Casgevy, which may yield a slower revenue ramp than optimistic projections suggest. For investors, CRSP represents a high-conviction play on genomic medicine, offering significant upside if execution succeeds, though volatility remains inherent to its stage of maturity.

Category Ratings

Biotech Stocks
4.7
Growth Stocks
4.3
Healthcare Stocks
4.0
Feb 12, 2026
AI-Generated Review Generated via Google API. This is an automated evaluation, not a consumer review. Learn more
CRISPR Therapeutics Screenshot

Added: Feb 11, 2026

crisprtx.com

Categories

Biotech Stocks Growth Stocks Healthcare Stocks